RecruitingHER2-Positive Solid Tumor
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Sponsor: Yuhan Corporation
You may qualify if…
- ✓ \[Dose Escalation Part\]
- ✓ Pathologically confirmed HER2-positive
- ✓ Mandatory provision of tumor tissue sample
- ✓ \[Dose Expansion Part\]
- ✓ Patients who have at least one measurable lesion
- ✓ Mandatory provision of tumor tissue sample
- ✓ 1. Cohort 1: Pathologically confirmed HER2-positive biliary tract cancer
- ✓ 2. Cohort 2: Pathologically confirmed HER2-positive metastatic solid tumor malignancy other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer
You may not qualify if…
- ✕ Uncontrolled central nervous system (CNS) metastases
- ✕ Spinal cord compression
- ✕ Carcinomatous meningitis
- ✕ Acute coronary syndromes
- ✕ Heart failure
- ✕ Interstitial lung disease (ILD)
- ✕ Pneumonitis
- ✕ History of a second primary cancer
Where it's recruiting
Massachusetts
Boston
Tennessee
Nashville
Source: ClinicalTrials.gov · NCT05523947 · last updated 2026-06-11